SCHEMBL6675427

SCHEMBL6675427

COc1ccc(NS(=O)(=O)c2c(F)c(Cl)c(F)c(Cl)c2F)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.50
ALDH1A1 P00352 6/20 0.48
HTT P42858 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
THRB P10828 2/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 2/20 0.48
TSHR P16473 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.46
HPGD P15428 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
GAA P10253 1/20 0.43
WDR5 P61964 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6675555 0.95 LMNA (0.48) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6089371 0.89 CA1 (0.50) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6086613 0.88 CA1 (0.49) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6088076 0.88 CA1 (0.49) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6677831 0.87 LMNA (0.56) LMNAALDH1A1HTTMEN1KMT2A
Batabulin SCHEMBL7103854 0.85 LMNA (0.48) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6681264 0.85 HTR6 (0.47) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6673889 0.83 LMNA (0.58) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL6676083 0.82 HTR6 (0.46) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL7536397 0.82 L3MBTL1 (0.44) LMNAALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed
EP-1005453-B1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS TULARIK INC (US) 2004-10-27 EP disclosed
EP-1090014-B1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC (US) 2003-09-03 EP disclosed
US-6417176-B2 ANTICANCER AGENTS, PSORIASIS, RESTENOSIS, ATHEROSCLEROSIS TULARIK, INC. 2002-07-09 US disclosed
US-6388131-B2 Benzenesulfonamide compounds, which encompasses the compound batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene) TULARIK, INC. 2002-05-14 US disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
US-20010018430-A1 Arylsulfonanilide phosphates TULARIK, INC. 2001-08-30 US disclosed
EP-1090014-A1 ARYLSULFONANILIDE PHOSPHATES Tularik Inc. (US) 2001-04-11 EP disclosed
US-6211167-B1 ANTICHOLESTEROL, ANTIPROLIFERATIVE AND ANTILIPEMIC AGENTS; CANCER, PSORIASIS, ATHEROSCLEROSIS, INFECTION AND VASCULAR RESTENOSIS TREATMENT TULARIK INC. 2001-04-03 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999067258-A1 ARYLSULFONANILIDE PHOSPHATES TULARIK INC. (US) 1999-12-29 WO disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 LMNA 2006/4885ALDH1A1 1173/4885HTT 4439/4885
US-20010018430-A1 Arylsulfonanilide phosphates PIK3CA, INPP5D, INPPL1 LMNA 3419/4885ALDH1A1 4237/4885HTT 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.